Bile Duct Tumors Medication

Updated: Apr 27, 2022
  • Author: Todd A Nickloes, DO, FACOS; Chief Editor: John Geibel, MD, MSc, DSc, AGAF  more...
  • Print

Medication Summary

Few patients are diagnosed with early-stage resectable tumors. Guidelinesfor unresectable or metastatic disease include various chemotherapy regimens. [24]

In April 2020, the FDA approved pemigatinib, the first targeted therapy for cholangiocarcinoma with FGFR2 fusion or rearrangement.


FGFR Inhibitors

Class Summary

Inhibition of FGFR disrupts tumor cell proliferation, survival, migration, and angiogenesis.

Pemigatinib (Pemazyre)

Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2, and 3 by inhibiting FGFR1-3 phosphorylation and signaling. Indicated for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.